This was a retrospective observational cohort study. This study was a secondary analysis of individuals with sickle cell disease (SCD) enrolled in the GRNDaD registry.
Study Type
OBSERVATIONAL
Enrollment
1,665
Novartis Pharmaceuticals
East Hanover, New Jersey, United States
Number of Patients in the Globin Research Network for Data and Discovery (GRNDaD) Registry who Received a Disease Modifying Therapy (DMT)
DMTs included: hydroxyurea, voxelotor, crizanlizumab, l-glutamine, and chronic red cell transfusion.
Time frame: Up to 2 years
Number of Patients in the Globin Research Network for Data and Discovery (GRNDaD) Registry Using Hydroxyurea Categorized by Gender
Time frame: Up to 2 years
Number of Patients in the GRNDaD Registry Using Hydroxyurea Categorized by Genotype
Time frame: Up to 2 years
Number of Patients in the GRNDaD Registry Using Hydroxyurea Categorized by Age
Time frame: Up to 2 years
Number of Patients in the GRNDaD Registry Using Voxelotor Categorized by Gender
Time frame: Up to 2 years
Number of Patients in the GRNDaD Registry Using Voxelotor Categorized by Genotype
Time frame: Up to 2 years
Number of Patients in the GRNDaD Registry Using Voxelotor Categorized by Age
Time frame: Up to 2 years
Number of Patients in the GRNDaD Registry Using Crizanlizumab Categorized by Gender
Time frame: Up to 2 years
Number of Patients in the GRNDaD Registry Using Crizanlizumab Categorized by Genotype
Time frame: Up to 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Number of Patients in the GRNDaD Registry Using Crizanlizumab Categorized by Age
Time frame: Up to 2 years
Number of Patients in the GRNDaD Registry Using L-glutamine Categorized by Gender
Time frame: Up to 2 years
Number of Patients in the GRNDaD Registry Using L-glutamine Categorized by Genotype
Time frame: Up to 2 years
Number of Patients in the GRNDaD Registry Using L-glutamine Categorized by Age
Time frame: Up to 2 years
Number of Patients in the GRNDaD Registry Using Chronic Transfusion Categorized by Gender
Time frame: Up to 2 years
Number of Patients in the GRNDaD Registry Using Chronic Transfusion Categorized by Genotype
Time frame: Up to 2 years
Number of Patients in the GRNDaD Registry Using Chronic Transfusion Categorized by Age
Time frame: Up to 2 years
Number of Hospital Admissions Categorized by Age
Time frame: Up to 2 years
Mean Number of Hospital Admissions
Time frame: Up to 2 years
Number of Emergency Department Visits Categorized by Age
Time frame: Up to 2 years
Mean Number of Emergency Department Visits
Time frame: Up to 2 years